Eric C. Zalamea, M.B.A.
Mr. Zalamea is an accomplished global commercialization expert with extensive background in rapid product growth and early strategic marketing of pharmaceutical and biologic products in multiple therapeutic areas. His successes in global commercialization have launched several brands that achieved multi-billion dollar revenues.
Mr. Zalamea was responsible for the pre-launch strategy through to execution of worldwide product launches for Merck’s innovative anesthesia drug. Developed and implemented paradigm shifting strategies aimed at stretching brand goals to achieve near blockbuster peak sales potential and has been launched in over 42 markets worldwide under his management. Mr. Zalamea also commercialized a specialty monoclonal antibody biologics drug for Novartis in respiratory immunology. His strategic work included development of multi-stakeholder solutions to fix issues in supply & distribution, patient education, product fulfillment and reimbursement. These product solutions paved the way for successful launches in Europe and Latin America while preparing the market for commercialization in the rest of the world and contributed to the early achievement of over $1 billion revenues in just four years.
His broad experience in building brands for Merck & Co., Novartis, Bayer and GlaxoSmithKline places him among the best and brightest pharmaceutical marketing professionals. Mr. Zalamea holds an MBA from J.L.Kellogg Graduate School of Management at Northwestern University and MBA coursework on Mergers & Acquisition at Manchester Business School, UK.
Kent M. Payne, Ph.D.
Dr. Payne combines broad business leadership and successful P&L track records. He has strategically led and grown enterprise value in pharmaceutical and biologics markets. Over the last 12 years he has held executive leadership positions of increasing responsibility within Cardinal Health and then Catalent Pharma Solutions, Inc. (a Blackstone Group company formed in 2007). He consistently embeds a culture of rigorous compliance, operational excellence and continuous improvement.
Among his many accomplishments at Catalent, Dr. Payne led the Biologics business' geographic expansion into: Europe, Asia and Latin America, including executing a partnership deal in Japan. He successfully developed Catalent’s Biologics strategy, transforming a cash negative technology offering through focused sales and marketing investments and operational discipline. He is recognized for his skill in identifying and developing talent. He has a reputation as a troubleshooter, taking on challenged businesses and providing profitable solutions. With these strengths, he has excelled in both startup and turn around business environments.
Jurij Petrin, M.D.
Dr. Petrin is an internationally recognized R&D leader who has built an extensive global regulatory affairs and clinical research network extending into 90 countries. His leadership and strategic planning has contributed to the successful international registration, approval and launch of many products including several generating multi-billion dollar annual revenue streams.
He spent 10 years with Bristol-Myers Squibb in Europe and the US, first as Medical Director for Eastern Europe and later as Executive Director and finally Vice President for Intercontinental Regulatory Science. He organized and supervised BMS’ international filings and approvals of new and supplemental submissions for several key specialty brands. He later started two companies, Pharmaceutical Regulatory Services, Inc. and PRS Clinical Inc., which provide drug development support to pharmaceutical companies.
Cecille D. Zalamea, M.B.E.
Ms. Zalamea is a seasoned marketing executive with product management experience ranging from consumer products to pharmaceutical market research. She was responsible for the successful brand development of the Mothers Aids franchise of Johnson & Johnson, Philippines. She later took on the role of Senior Project Manager of Oncology at a market research firm based in Basel, Switzerland. Her consumer and pharmaceutical marketing experience allowed her to effectively work on consulting projects in the emerging cosmeceuticals and nutraceutical businesses in the USA.